Claims-based ATTR-CM incidence increased >4-fold in Medicare (2010–2021) and ~2.7-fold in commercial insurance (2016–2022), with parallel multi-fold prevalence increases across databases. Higher rates ...
ATTR-cardiac amyloidosis (ATTR-CM) is a progressive heart condition often mistaken for normal aging. For years, communication in the category has focused on urgency and decline, leaving patients with ...
Open-label extension data from 389 ATTRibute-CM completers compared continuous acoramidis with placebo-to-acoramidis crossover, after mandated tafamidis discontinuation. Continuous acoramidis exposure ...
BridgeBio Pharma is teaming up with BlackDoctor and HealthyWomen to highlight how the heart condition ATTR-cardiac amyloidosis (ATTR-CM) is being “systematically missed in women.” The condition is a ...
Kevin M. Alexander, MD, reflects on ACC data for ATTR-CM and its implications for patient care, stressing that clinical trials and extension analyses show ATTR therapies extend survival, improve ...
In ATTR amyloidosis, a buildup of harmful proteins causes damage to tissues and organs throughout the body, including the heart. Over time, the condition can progress from stage 1, which may cause ...
Alnylam has big ambitions for Amvuttra. But despite an explosive transthyretin amyloid cardiomyopathy (ATTR-CM) launch in 2025, three questions remain: potential upcoming competition from AstraZeneca ...
Is rhythm control underused in ATTR-CM? Drs Kevin Alexander and Ronald Witteles make the case for rethinking how we manage arrhythmias in this disease. Is rhythm control underused in ATTR-CM? Drs ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced a set of strategic efforts designed to accelerate earlier ...
His voice is easily among the most recognizable in the world. Award-winning actor Morgan Freeman has a presence that can command a room without stepping into it. On and off screen, his steady baritone ...
Life expectancy for people with ATTR amyloidosis varies, generally ranging from 3 to 15 years after symptoms appear, and depends on the specific type of the condition and any other health issues a ...
Among the 175 patients without atrial fibrillation at baseline, 41% developed new-onset atrial fibrillation over a median follow-up of 2 years. Over 50% of patients with transthyretin-mediated amyloid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results